Join Mayo Clinic Laboratories and Lucence for our webinar exploring how LiquidHALLMARK®, a cutting-edge liquid biopsy test, is transforming cancer care. Designed for oncologists, laboratory directors, and healthcare professionals, this livestream event will introduce you to a revolutionary approach to cancer testing. LiquidHALLMARK® uses next-generation sequencing to target both DNA and RNA circulating in the blood to help physicians better understand a patient’s cancer, offering data that may be unavailable from other commercially available liquid biopsy tests.

On Tuesday, Oct. 28, 2025, from noon to 1 p.m. CDT, discover how LiquidHALLMARK® offers advantages over other commercially available liquid biopsy testing by identifying a broader range of genetic mutations. This testing opens the door to more targeted and effective treatment strategies, which can lead to improved outcomes for patients. The webinar will be led by Matthew Binnicker, Ph.D., chief scientific officer at Mayo Clinic Laboratories, and Min-Han Tan, M.B.B.S., FRCP, Ph.D., founder and CEO of Lucence.

Don't miss this opportunity to learn how LiquidHALLMARK® is setting a new standard in cancer diagnostics.

For questions, contact us at mcleducation@mayo.edu.

Credit: LiquidHALLMARK® is a trademark or registered trademark of Lucence Health Inc. and/or its affiliates in the U.S. and other countries and is used under license.